Expansion and distribution of novel ngcms
Ended Awarded Last action
- Contract number
- 75N91020F00036
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,129,629
Award facts
- Contract value 100% obligated
- $2,129,629.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,129,629 |
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $2.1 million delivery order contract to Leidos Biomedical Research Inc. to support the expansion and distribution of next generation cancer models for the agency's Human Cancer Model Initiative. Under the cost plus fixed fee contract holding a period of performance from September 2020 through November 2022, Leidos will utilize a subcontract with the American Type Culture Collection to further develop and distribute novel next generation cancer models to the research community. The delivery order was issued against an unspecified indefinite-delivery/indefinite-quantity contract vehicle to advance the National Cancer Institute's goal of accelerating precision cancer medicine through improved disease modeling and preclinical research capabilities.
Quick answers
Who was awarded contract 75N91020F00036?
75N91020F00036 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2020.
How much is contract 75N91020F00036 worth?
The government has obligated $2,129,629 on 75N91020F00036.
Is contract 75N91020F00036 an order under another contract?
Yes. 75N91020F00036 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00036 competed?
The extent of competition for 75N91020F00036 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award